Skip to main navigation

About People Science Pipeline Patients Investors Careers

Overview
Vision & Values
Impact
Founder's Letter
Contact

Overview
Leadership Team
Board of Directors
Scientific Advisory Board
R&D Advisory Board

RAS/MAPK Pathway
MAPKlamp & More
Presentations & Publications

Pipeline
Programs
Clinical Trials

Patients & Caregivers
Clinical Trials

Corporate Overview
News & Events
Stock Information
Corporate Governance
Financial Information
Investor Resources

Dynamic Culture
Values & Attributes
Competitive Benefits
Open Positions

Stay in Touch

858.465.6511
info@erasca.com

News & Events

News Releases
Erasca in the News
Events
Presentations

News Releases

Year

11.12.2024

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

11.05.2024

Erasca to Present at Upcoming Investor Conferences

10.24.2024

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

09.25.2024

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

08.29.2024

Erasca to Present at Upcoming Investor Conferences in September

08.12.2024

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

06.18.2024

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

05.29.2024

Erasca to Present at Upcoming Investor Conferences in June

05.21.2024

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

05.16.2024

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19

Site - Investor Tools

Contact Us

info@erasca.com

Location

ERASCA, INC.

3115 Merryfield Row

Suite 300

San Diego, CA 92121

Terms of Use
Privacy Policy

© 2021 Erasca™, Inc. All rights reserved.